13F-HR filed by Foresite Capital Management V, LLC
Foresite Capital Management V, LLC filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-14, with 9 holding rows worth $362,202,120.
- Accession
- 0001104659-26-097121
- Filer
- CIK 1792206
- Filed
- 2026-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2026
A holdings report, 9 entries on the cover page, a total value of $362,202,120 stated on the cover page (in dollars after the unit check, H1), rows summing to $362,202,120 with VALUE read as dollars as filed, 13F file number 028-20850. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ALUMIS INC | 022307102 | COM | 5,896,995 | $165,941,439 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 1,079,050 | $76,666,503 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 374,069 | $27,359,407 | dollars as filed | |
| HIMS & HERS HEALTH INC | 433000106 | COM CL A | 738,151 | $25,591,695 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 664,142 | $22,966,030 | dollars as filed | |
| EIKON THERAPEUTICS INC | 282564103 | COMMON STOCK | 1,318,983 | $17,212,728 | dollars as filed | |
| Odyssey Therapeutics, Inc. | 67613T104 | COMMON STOCK | 713,105 | $13,342,195 | dollars as filed | |
| LYELL IMMUNOPHARMA INC COM NEW | 55083R203 | Stock | 476,386 | $6,693,223 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 265,000 | $6,428,900 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-26-097121 | this filing | 2026-08-14 | acceptance time not in the bulk data set |